10/9/2007

Teva Pharmaceutical Industries Ltd. has obtained FDA approval to launch its generic version of Actonel, Procter & Gamble Co.'s treatment for osteoporosis in postmenopausal women. The regulatory approval of Teva's Risedronate Sodium tablets comes amid a pending patent suit filed by P&G against the Israeli drugmaker.

Related Summaries